Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1404: Pembrolizumab vs Interferon/Ipilimumab in High Risk Resected Melanoma
2024-516881-12-00Phase 3Authorised
- Sponsor
- Cancer Trials Ireland
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised trial of pembrolizumab in melanoma (3 arms), sponsored by Cancer Trials Ireland. Primary endpoints: Progression/Relapse, Relapse-Free Survival and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516881-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516881-12-00.